Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.2 per share when it actually produced a loss of $0.2, delivering no surprise. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Exagen, which belongs to the Zacks Medical - Products ...